- In this section:
- Contact our JPT Peptide Technologies specialists
Benefits of using the PepMix Peptide Pools
• Simultaneous CD4 and CD8 response detection in a single sample (CEF pools: CD8 only)
• Better or equivalent T-cell response stimulation compared to whole protein antigens
• Improved and easier T-cell response detection in stored blood and PBMCs compared to whole protein antigens
• Reliable quality control and quality assurance
• High batch-to-batch reproducibility
• Prolonged shelf life when stored freeze-dried
• Pooled and aliquoted according to ISO 9001:2008 and GCLP regulations
Testimonials
"I have used JPT's peptide pools (PepMix) for years now, with great satisfaction! First CMV derived peptides and now also EBV. So far, we have published data in one publication and plan several more in the near future."
Anna Karin Lidehaell, Uppsala University, Clin. Immunol., Uppsala, Sweden
PepMix Peptide Pools applications
• Vaccine efficacy testing
• Antigen specific T-cell response measurement
• Antigen-specific T-cell responses correlation with immune status
• Antigen specific T-lymphocyte generation for adoptive immunotherapy
• T-lymphocyte epitope discovery
PepMix Peptide Pool Range
1. Positive and negative control pools
Including CEF, CEFT and EF Pools, HCMV (pp65, IE-1...), Human Actin
2. Infectious disease pools
Including EBV (EBNAs, BLZF1...), BKV (VP1, largeT...), Adenovirus, HPV, HIV, Influenza and many more
3. Tumour associated antigens
Including melanoma, prostate and breast cancer, glioma, gastric cancer, testicular/ovarian cancer, Wilms tumour and many more
Material available for download
Cytomegalovirus protein spanning PepMix peptide pools to discover changes in T cell immunity in the aging population
T cell therapy for viral infections after hematopoietic stem cell transplant
Qualification and use of peptide libraries for clinical trial immunomonitoring
Products
Note: product availability depends on country - see product detail page.
Details | Cat number & supplier | Size | Price |
PepMix Human (Tyrosinase-related protein 2) PM-TRP-2 · JPT Peptide Technologies | PM-TRP-2 JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£696.00
15 nmol (~25 µg) per peptide
view
|
PepMix Human (WT1/WT33) PM-WT1 · JPT Peptide Technologies | PM-WT1 JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£631.00
15 nmol (~25 µg) per peptide
view
|
PepMix Influenza A (HA /Brisbane (H1N1)) PM-INFA-HABris · JPT Peptide Technologies | PM-INFA-HABris JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£696.00
15 nmol (~25 µg) per peptide
view
|
PepMix Influenza A (HA /California (H1N1)) PM-INFA-HACal · JPT Peptide Technologies | PM-INFA-HACal JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£696.00
15 nmol (~25 µg) per peptide
view
|
PepMix Influenza A (MP1 (H3N2)) PM-INFA_MP1 · JPT Peptide Technologies | PM-INFA_MP1 JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£645.00
15 nmol (~25 µg) per peptide
view
|
PepMix Influenza A (MP1 /California (H1N1)) PM-INFA-MP1-H1N1 · JPT Peptide Technologies | PM-INFA-MP1-H1N1 JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£645.00
15 nmol (~25 µg) per peptide
view
|
PepMix Influenza A (MP1/AnnArbor (H2N2) PM-INFA-MP1H2N2 · JPT Peptide Technologies | PM-INFA-MP1H2N2 JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£645.00
15 nmol (~25 µg) per peptide
view
|
PepMix Influenza A (MP2 /California (H1N1)) PM-INFA_MP2 · JPT Peptide Technologies | PM-INFA_MP2 JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£598.00
15 nmol (~25 µg) per peptide
view
|
PepMix Influenza A (MP2/AnnArbor (H2N2) PM-INFA-MP2H2N2 · JPT Peptide Technologies | PM-INFA-MP2H2N2 JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£598.00
15 nmol (~25 µg) per peptide
view
|
PepMix Influenza A (Neuraminidase/Turkey/1/2005(H5N1)) PM-INFA-NATur · JPT Peptide Technologies | PM-INFA-NATur JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£696.00
15 nmol (~25 µg) per peptide
view
|
PepMix Influenza A (Neuroamidase /California (H1N1) PM-INFA_NA · JPT Peptide Technologies | PM-INFA_NA JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£696.00
15 nmol (~25 µg) per peptide
view
|
PepMix Influenza A (NP (H3N2)) PM-INFA_NP · JPT Peptide Technologies | PM-INFA_NP JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£696.00
15 nmol (~25 µg) per peptide
view
|
PepMix Influenza A (NP/AnnArbor (H2N2) PM-INFA-NPH2N2 · JPT Peptide Technologies | PM-INFA-NPH2N2 JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£696.00
15 nmol (~25 µg) per peptide
view
|
PepMix Vaccinia virus (MVA105L) PM-MVA-105L · JPT Peptide Technologies | PM-MVA-105L JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£645.00
15 nmol (~25 µg) per peptide
view
|
PepMix Vaccinia virus (MVA018L) PM-MVA-018L · JPT Peptide Technologies | PM-MVA-018L JPT Peptide Technologies |
15 nmol (~25 µg) per peptide |
£598.00
15 nmol (~25 µg) per peptide
view
|